Injunction against Shkreli in Daraprim case should be affirmed, AAI argues

( March 30, 2023, 22:31 GMT | Official Statement) -- MLex Summary: The American Antitrust Institute told a US appeals court that precedent shows that the Federal Trade Commission’s core mission of preserving competition depends on the injunctive relief that it can obtain and an injunction cannot be effective unless it prevents future antitrust violations at the same time it redresses current harms. AAI called for the affirmance of an injunction and fine against Martin Shkreli for engaging in a scheme to insulate toxoplasmosis drug Daraprim from generic competition. “Martin Shkreli’s request of this Court to narrow the district court’s injunction is especially dangerous. It would widen the paths for a proven recidivist to cause further harm to vulnerable pharmaceutical patient populations,” AAI argued.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Injunction against Shkreli in Daraprim case should be affirmed, AAI argues

Prepare for tomorrow’s regulatory change, today

Documents

Related Sections